Research Groups

Related Links

Dr Anne Armstrong

Anne Armstrong carries out clinical studies of new treatments in breast cancer and leads trials of investigational agents in triple negative disease.

Consultant in Medical Oncology and Honorary Senior Lecturer

The Christie NHS Foundation Trust
550 Wilmslow Road
M20 4BX

I am a Consultant Medical Oncologist specialising in breast cancer.

After qualifying from Bristol University in 1995 I underwent specialist training at The Christie. I was awarded a PhD from The University of Manchester in 2002 investigating the use of vaccines against cancer.

In 2007 I was appointed as a Consultant Medical Oncologist at The Christie NHS Foundation Trust and subsequently as an Honorary Senior Lecturer at The University of Manchester.

I am actively involved in clinical research and am a member of the NCRN Breast Clinical Studies Group and the NICE Familial Breast Cancer Guideline Development Group.

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. Ann Oncol. 2019 30 558-566

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.  

Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M.

Ann Oncol. 2019 30 774-780

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.

Robson M, Ruddy KJ, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Li W, Tung N, Armstrong A, Delaloge S, Bannister W, Goessl C, Degboe A, Hettle R, Conte P. Eur J Cancer. 2019 120 20-30

Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.

Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, Ali S, Cleator S, Kenny L, Stebbing J, Rutherford M, Sethi H, Boydell A, Swenerton R, Fernandez-Garcia D, Gleason KLT, Goddard K, Guttery DS, Assaf ZJ, Wu HT, Natarajan P, Moore DA, Primrose L, Dashner S, Tin AS, Balcioglu M, Srinivasan R, Shchegrova SV, Olson A, Hafez D, Billings P, Aleshin A, Rehman F, Toghill BJ, Hills A, Louie MC, Lin CJ, Zimmermann BG, Shaw JA. Clin Cancer Res. 2019 25 4255-4263

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

 Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P. Ann Oncol. 2019 30 405-411

Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations.

Grimmett C, Brooks C, Recio-Saucedo A, Armstrong A, Cutress RI, Gareth Evans D, Copson E, Turner L, Meiser B, Wakefield CE, Eccles D, Foster C. Support Care Cancer. 2019 27 297-309

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

Pascual J, Lim JSJ, Macpherson IRJ, Armstrong AC, Ring A, Okines AF, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, Hubank M, Hills M, King J, Parmar M, Prout T, Finneran L, Malia J, Swales KE, Ruddle R, Raynaud FI, Turner A, Hall E, Yap TA, Lopez JS, Turner NC. Cancer Discov. 2020 Online ahead of print.



We manage a broad portfolio of phase I-III studies within the breast disease group, amongst these we lead trials of investigational agents in triple-negative disease.

We are also interested in fertility concerns after a diagnosis of breast cancer and carry out qualitative studies in this area.

Patient derived mammosphere and xenograft tumour initiation correlates with progression to metastasis.

Eyre R, Alferez D, Spence K, Kamal M, Shaw FL, Simoes BM, Santiago-Gomez A, Bramley M, Absar M, Saad Z, Chatterjee S, Kirwan C, Gandhi A, Armstrong AC, Wardley AM, O’Brien CS, Farnie G, Howell SJ and Clarke RB.

J Mammary Gland Biology and Neoplasia. 2016 Sep 28. [Epub ahead of print]


A phase II trial of low dose estradiol in postmenopausal women with advanced breast cancer and acquired resistance to aromatase inhibition.  


Zuccini G, Armstrong AC, Wardley AM, Wilson G, Misra V, Seif M, Ryder WD, Cope J, Blowers E, Howell A, Palmieri C, Howell SJ.

European Journal of Cancer. 2015 Dec;51(18):2725-31


Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.


Earl HM, Hiller L, Dunn JA, Blenkinsop C, Grybowicz L, Vallier AL, Abraham J, Thomas J, Provenzano E, Hughes-Davies L, Gounaris I, McAdam K, Chan S, Ahmad R, Hickish T, Houston S, Rea D, Bartlett J, Caldas C, Cameron DA, Hayward L; ARTemis Investigators.

Lancet Oncol. 2015 Jun;16(6):656-66. doi: 10.1016/S1470-2045(15)70137-3.


Management of women at high risk of breast cancer.


Armstrong AC, Evans GD.

BMJ. 2014 Apr 28;348:g2756. doi: 10.1136/bmj.g2756.


Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial.


André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L.

Lancet Oncol. 2014 May;15(6):580-91. doi: 10.1016/S1470-2045(14)70138-X.


Is it me or is it hot in here? A plea for more research into hot flushes.


Morgan A, Fenlon DR; National Cancer Research Institute Clinical Studies Group Breast Cancer Working Party on Symptom Management.

Clin Oncol (R Coll Radiol). 2013 Nov;25(11):681-3. doi: 10.1016/j.clon.2013.07.008.


Emerging targeted combinations in the management of breast cancer.


Lee RJ, Armstrong AC, Wardley AM.

Breast Cancer (Dove Med Press). 2013 Aug 13;5:61-72. doi: 10.2147/BCTT.S26771.


Letrozole: advancing hormone therapy in breast cancer.


Lee RJ, Armstrong AC, Wardley AM.

Womens Health (Lond Engl). 2012 Nov;8(6):611-8. doi: 10.2217/whe.12.49.


Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein?


Armstrong AC, Gilham DE.

Breast Cancer Res. 2012 May 30;14(3):106.


Breast-cancer adjuvant therapy with zoledronic acid.


Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators.

N Engl J Med. 2011 Oct 13;365(15):1396-405. doi: 10.1056/NEJMoa1105195.


Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer.


Lee RJ, Wakefield A, Foy S, Howell SJ, Wardley AM, Armstrong AC.

Psychooncology. 2011 Oct;20(10):1044-52. doi: 10.1002/pon.1826.


Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.

Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C.

Breast Cancer Res Treat. 2010 Apr;120(2):461-7. doi: 10.1007/s10549-010-0747-9.


Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.


Howell SJ, Wardley AM, Armstrong AC.

J Natl Cancer Inst. 2009 Dec 16;101(24):1730; author reply 1730-1. doi: 10.1093/jnci/djp390.

Management of cancer from an unknown primary.

Armstrong AC, Blackhall FH.

Expert Opin Pharmacother. 2007 Mar;8(4):445-55.